NNC0487-0111 in People With Reduced or Normal Liver Function
Studies how NNC0487-0111 behaves in the body and its safety in adults with liver impairment.
Plain-language title generated from the registry record
Registry title: A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
Key facts
- Where
- Bratislava and Malacky, SlovakiaSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07587710, who can take part
Where in Slovakia
- Summit Clinical Research s.r.oBratislava, SlovakiaTaking people
- Summit Clinical Research s.r.o.Malacky, SlovakiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07587710
- Record updated
- 10 November 2026
- Original description
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.Read full original descriptionShow less
A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.
Inclusion: Male or female (sex at birth); Age 18-80 years (both inclusive) at the time of signing informed consent; Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.
Exclusion: Known or suspected hypersensitivity to study intervention(s) or related products; Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.